Trial Profile
A multi-centric, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of ZYH1 compared to Pioglitazone 45mg in dyslipidemia with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2019
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary) ; Pioglitazone
- Indications Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Acronyms PRESS V
- Sponsors Cadila Healthcare
- 28 Nov 2012 Planned number of patients changed from 120 to 122 as reported by Clinical Trials Registry - India record.
- 19 Jul 2012 Actual initiation date changed from 19 Aug 2009 to 27 Jul 2009 as reported by Clinical Trials Registry - India record.
- 08 Sep 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.